PRODUCT DATA SHEET



Bioworld Technology, Inc.

Recombinant Murine Vascular Endothelial Growth Factor 165 (rMuVEGF165)

Catalog Number: PR2038 Source: Escherichia coli. Quantity: 2µg/10µg/1.0mg

Description

VEGF was initially purified from media conditioned by normal bovine pituitary folliculo-stellate cells and by a variety of transformed cell lines as a mitogen specific for vascular endothelial cells. It was subsequently found to be identical to an independently discovered vascular permeability factor (VPF), which was previously identified in media conditioned by tumor cell lines based on its ability to increase the permeability of capillary blood vessels. Three mouse cDNA clones, which arise through alternative splicing and which encode mature mouse monomeric VEGF having 120, 164, or 188, amino acids, respectively, have been identified. Two receptor tyrosine kinases (RTKs), Flt-1 and Flk-1 (the mouse homologue of human KDR), both members of the type III subclass of RTKs containing seven immunoglobulin-like repeats in their extracellular domains, have been shown to bind VEGF with high affinity. The roles of the homodimers of KDR, Flt, and the heterodimer of KDR/Flt in VEGF signal transduction remain to be elucidated. In vivo, VEGF has been found to be a potent angiogenesis inducer.

Molecular Weight:

Recombinant murine VEGF165 is a 39.0 kDa disulfidelinked homodimeric protein consisting of two 165 amino acid polypeptide chains.

Purity:

>95% by SDS-PAGE and HPLC analyses

Biological Activity:

Tel: 6123263284

Measured by its ability to stimulate 3H-thymidine incorporation in HUVE cells. The ED50 for this effect is typically 2 - 4 ng/mL, corresponding to a Specific Activity of $\Box 2.5 \times 105$

IU/mg.

Physical Appearance:

Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation:

Lyophilized from a 0.2mm filtered solution in PBS, pH 7.4.

AA Sequence:

MAPTTEGEQKSHEVIKFMDVYQRSYCR
PIETLVDIFQEYPDEIEYIFKPSCVPLMR
CAGCCNDEALECVPTSESNITMQIMRIK
PHQSQHIGEMSFLQHSRCECRPKKDRT
KPEKHCEPCSERRKHLFVQDPQTCKCS
CKNTDSRCKARQLELNERTCRCDKPRR

Endotoxin:

Less than 1EU/mg of rmVEGF165 as determined by LAL method

Reconstitution:

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at <-20°C. Further dilutions should be made in appropriate buffered solutions.

Storage:

Tel: 0086-025-86371664

This lyophilized preparation is stable at 2-8°C, but should be kept at -20°C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8°C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20°C to -70°C. Avoid repeated freeze/thaw cycles.

MADE IN CHINA

Bioworld technology, co, Ltd.

No 9, weidi road Qixia District Nanjing, 210046, P, R.China.

Email: info@biogot.com Fax:0086-025-86213570

Fax: 6122933841

PRODUCT DATA SHEET

Usage:

HUMAN USE. Made in China

This material is offered by USA Bioworld biotech for research, laboratory or further evaluation purposes. NOT FOR

Bioworld Technology, Inc.

1660 South Highway 100, Suite 500 St. Louis Park,MN 55416,USA. Email: info@bioworlde.com

Tel: 6123263284 Fax: 6122933841

Bioworld technology, co, Ltd.

MADE IN CHINA

No 9, weidi road Qixia District Nanjing, 210046, P, R.China.

Email: info@biogot.com
Tel: 0086-025-86371664 Fax:0086-025-86213570